OpenAlex
PricingAboutJobs
Log inGet started
Work

FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer

HTML

Year: 2020
Type: article
Source: Clinical Cancer Research
DOI: 10.1158/1078-0432.ccr-20-3119
Authors: Sakar Wahby, Lola Fashoyin-Aje, Christy L. Osgood, Joyce Cheng, Mallorie H. Fiero, Lijun Zhang, Shenghui Tang, Salaheldin S. Hamed, Pengfei Song, Rosane Charlab, Sarah E. Dorff, Tiffany K. Ricks, Kimberly Barnett-Ringgold, Jeannette Dinin, Kirsten B. Goldberg, Marc R. Theoret, Richard Pazdur, Laleh Amiri-Kordestani, Julia A. Beaver
Institutions: United States Food and Drug Administration, Center for Drug Evaluation and Research
Language: English

Topic: Breast Cancer Treatment Studies
Subfield: Cancer Research
Field: Biochemistry, Genetics and Molecular Biology
Domain: Life Sciences
Keywords: sacituzumab govitecan, metastatic triple-negative breast cancer, accelerated approval, third-line therapy, objective response rate, duration of response, adverse effects, antibody-drug conjugates
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W3103281894
FWCI: 4.478
Cites: 16
Cited by: 171
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Subscribe
Supporters
Legal
Privacy
Accessibility
Terms
Security